Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BioNexus Gene Lab (BGLC) Total Current Liabilities (2018 - 2025)

BioNexus Gene Lab's Total Current Liabilities history spans 8 years, with the latest figure at $520957.0 for Q4 2025.

  • Quarterly results put Total Current Liabilities at $520957.0 for Q4 2025, down 73.3% from a year ago — trailing twelve months through Dec 2025 was $520957.0 (down 73.3% YoY), and the annual figure for FY2025 was $520957.0, down 73.3%.
  • Total Current Liabilities for Q4 2025 was $520957.0 at BioNexus Gene Lab, down from $678023.0 in the prior quarter.
  • In the past five years, Total Current Liabilities ranged from a high of $3.0 million in Q1 2021 to a low of $520957.0 in Q4 2025.
  • The 5-year median for Total Current Liabilities is $1.7 million (2023), against an average of $1.8 million.
  • The sharpest move saw Total Current Liabilities skyrocketed 6882.74% in 2021, then tumbled 73.3% in 2025.
  • Year by year, Total Current Liabilities stood at $2.3 million in 2021, then fell by 13.94% to $2.0 million in 2022, then decreased by 18.62% to $1.6 million in 2023, then increased by 19.64% to $2.0 million in 2024, then tumbled by 73.3% to $520957.0 in 2025.
  • According to Business Quant data, Total Current Liabilities over the past three periods came in at $520957.0, $678023.0, and $1.8 million for Q4 2025, Q3 2025, and Q2 2025 respectively.